Fig. 2
Overall survival of patients in two groups mOS: D-TACE + Donafenib + Tislelizumab group, 19.2 months (95%CI 16.7–21.3 months); D-TACE + Sorafenib group, 12.3 months (95%CI 7.4–14.6 months).
Fig. 2 | Scientific Reports
Overall survival of patients in two groups mOS: D-TACE + Donafenib + Tislelizumab group, 19.2 months (95%CI 16.7–21.3 months); D-TACE + Sorafenib group, 12.3 months (95%CI 7.4–14.6 months).
